Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial The Lancet Gastroenterology & Hepatology

https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00071-8/abstract?dgcid=raven_jbs_etoc_feature_langas